New Indications for Established Drugs: Combined Tumor-Stroma-Targeted Cancer Therapy with PPAR&ggr; Agonists, COX-2 Inhibitors, mTOR Antagonists and Metronomic Chemotherapy

By  

Current Cancer Drug Targets, Vol. 5, Iss. 6, 2005-09 ,pp. : 393-419

Bentham Science Publishers

Access to resources Recommend Favorite

PPAR- agonists: therapeutic role in diabetes, inflammation and cancer

By Murphy G.J.   Holder J.C.  

Trends in Pharmacological Sciences, Vol. 21, Iss. 12, 2000-12 ,pp. : 469-474

Elsevier

Access to resources Recommend Favorite

Ameliorated Chemotherapeutic Potential of Diverse Dose Flouropyrimidine Therapy By Etodolac via NF-ΚB Pathway, PPAR-γ Expression and COX-II Inhibition in DMH Induced Colon Cancer Rats

By  

Clinical Cancer Drugs, Vol. 3, Iss. 2, 2016-10 ,pp. : 109-120

Bentham Science Publishers

Access to resources Recommend Favorite

The non-genomic crosstalk between PPAR-γ ligands and ERK1/2 in cancer cell lines

By Papageorgiou Efstathia   Pitulis Nea   Msaouel Pavlos   Lembessis Peter   Koutsilieris Michael  

Expert Opinion on Therapeutic Targets, Vol. 11, Iss. 8, 2007-08 ,pp. : 1071-1085

Informa Healthcare

Access to resources Recommend Favorite

New Pharmacological Perspectives and Therapeutic Potential of PPAR-&ggr; Agonists

By  

Current Pharmaceutical Design, Vol. 10, Iss. 28, 2004-11 ,pp. : 3505-3524

Bentham Science Publishers

Access to resources Recommend Favorite